Brief: Mustang Bio Receives European Medicines Agency Prime Designation For Mb-107 To Treat X-Linked Severe Combined Immunodeficiency In Newly Diagnosed Infants
02/08/2021 13:29
Aug 2 (Reuters) - Fortress Biotech Inc FBIO.O :
* MUSTANG BIO RECEIVES EUROPEAN MEDICINES AGENCY PRIME
DESIGNATION
FOR MB-107 TO TREAT X-LINKED SEVERE COMBINED IMMUNODEFICIENCY IN
NEWLY DIAGNOSED INFANTS
Source text for Eikon: ID:nGNXbPQckT
Further company coverage: FBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mustang Bio
See all newsAdvisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
U.S. STOCKS ON THE MOVE-Dow, Phibro, Mustang Bio
Mustang soars on FDA's orphan drug tag for brain cancer therapy
Mustang Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Mustang Bio Inc - Enters Sale And Surrender Agreement With Abbvie